U.S. Advanced Therapy Medicinal Products CDMO Market 2030: Unlocking the Future of Gene and Cell Therapies
The U.S. market for Advanced Therapy Medicinal Products (ATMPs) CDMOs was valued at an estimated USD 2.34 billion in 2023 and is projected to surge at a compelling compound annual growth rate (CAGR) of 18.29% from 2024 to 2030. This impressive growth is largely driven by the increasing incidence of rare and severe diseases, significant investments flowing into ATMP research and development (R&D), and the expanding trend of outsourcing within the pharmaceutical sector. The inherent complexity of manufacturing ATMPs, coupled with a growing need for specialized expertise and advanced technologies, has fueled the demand for CDMO (Contract Development and Manufacturing Organization) services. These organizations play a vital role in facilitating the development and successful commercialization of innovative therapies, thereby significantly contributing to market expansion. In 2023, the U.S. ATMP CDMO market commanded the largest share, holding over 40% of the global market. This leade...